missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human MYOZ1 (aa 132-208) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (81%), Rat (81%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-58137 (PA5-58137. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Sarcomere assembly is regulated by the muscle protein titin. Titin is a giant elastic protein with kinase activity that extends half the length of a sarcomere. It serves as a scaffold to which myofibrils and other muscle related proteins are attached. This gene encodes a protein found in striated and cardiac muscle that binds to the titin Z1-Z2 domains and is a substrate of titin kinase, interactions thought to be critical to sarcomere assembly. Mutations in this gene are associated with limb-girdle muscular dystrophy type 2G.
Specifications
Specifications
| Accession Number | Q9NP98 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 58529 |
| Name | Human MYOZ1 (aa 132-208) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2310001N11Rik; alpha-actinin binding protein; AV090278; calcineurin-2; calsarcin 2; calsarcin-2; CS-2; FATZ; filamin-, actinin- and telethonin-binding protein; MYOZ; myoz1; myozenin 1; myozenin precursor; myozenin-1; Protein FATZ; RGD1561064; skeletal muscle-specific protein |
| Common Name | MYOZ1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction